Improved delivery of molecularly targeted agents upon modulation of multidrug resistance efflux proteins at mouse blood brain barrier

MOspace/Manakin Repository

Breadcrumbs Navigation

Improved delivery of molecularly targeted agents upon modulation of multidrug resistance efflux proteins at mouse blood brain barrier

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/15990

[-] show simple item record

dc.contributor.advisor Mitra, Ashim K., 1954- en
dc.contributor.author Minocha, Mukul
dc.date.accessioned 2012-11-06T17:31:12Z
dc.date.available 2012-11-06T17:31:12Z
dc.date.issued 2012-11-06
dc.date.submitted 2012 Summer en
dc.identifier.uri http://hdl.handle.net/10355/15990
dc.description Title from PDF of title page, viewed on November 6, 2012 en
dc.description Dissertation advisor: Ashim K. Mitra en
dc.description Includes bibliographical references (p. 175-192) en
dc.description Vita en
dc.description Thesis (Ph.D.)--School of Pharmacy and Dept. of Chemistry. University of Missouri--Kansas City, 2012 en
dc.description.abstract Recurrent brain tumors are one of the most lethal forms of solid tumors with poor prognosis. Molecularly targeted therapy, inhibiting the tyrosine kinase domain of epidermal growth factor receptor (EGFR), platelet derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptors (VEGFR) is at the forefront of current clinical practice for management of highly vascularized brain tumors. However, current molecularly targeted agents used in clinical trials so far have shown limited clinical benefit to block tumor progression. It has now been well established that P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are the two major efflux proteins that restrict the entry of xenobiotics across BBB. Overexpression of these efflux pumps in brain tumors at the BBB further compromises brain penetration of anti-tumor agents. The broad objective of this dissertation project is to study the role of efflux on brain penetration of selected small molecule tyrosine kinase inhibitors; pazopanib and vandetanib. In vitro and in vivo results showed that the entry across the BBB for these drugs is limited via active efflux. This could be a plausible mechanism for inefficacy seen for these drugs in clinical trials when used as monotherapy. As a secondary aim of this investigation we wanted to develop a viable strategy to overcome efflux at the BBB by coadministering clinically relevant efflux modulators which could also impart a synergistic pharmacological effect in the treatment regimen. Erlotinib, canertinib, everolimus and temsirolimus were screened as potential modulators of P-gp and Bcrp1 activity. The fact that these drugs inhibit a different class of receptor population than pazopanib and vandetanib, offer a dual advantage for synergistic pharmacological effect in addition to the primary role of efflux modulation. Our results demonstrate that co-administration of selected clinically relevant efflux modulators can significantly enhance brain partitioning of pazopanib and vandetanib in mice and hence warrant further pre-clinical and clinical investigation. en_US
dc.description.tableofcontents Introduction -- Literature review -- Determination of pazopanib (gw-786034) in mouse plasma and brain tissue homogenate by high performance liquid chromatography-tandem mass spectrometry (hplc.ms-ms) -- P-glycoprotein and breast cancer resistance protein together limit brain accumulation of pazopanib; a multi-targeted tyrosine kinase inhibitor -- Differential impact of p-gp and bcrpi on brain disposition and plasma pharmacokinetics of vandetanib -- Enhanced brain accumulation of pazopanib by modulation of mdr efflus at bbb canertinib or erlotinib -- A co-administration strategy to enhance brain accumulation of vandetanib by modulation of mdr efflux at bbb by m-tor pathway inhibitors -- Effect of short term and chronic administration of sutherlandia frutescens on pharmacokinetics of nevirapine in rats -- Summary and recommendations -- Appendix en
dc.format.extent xviii, 193 pages en
dc.language.iso en_US en_US
dc.publisher University of Missouri--Kansas City en
dc.subject.lcsh Drug delivery systems en
dc.subject.lcsh Brain -- Tumors -- Treatment en
dc.subject.mesh Drug Delivery Systems en
dc.subject.mesh Brain Neoplasms en
dc.subject.other Dissertation -- University of Missouri--Kansas City -- Pharmacy en
dc.subject.other Dissertation -- University of Missouri--Kansas City -- Chemistry en
dc.title Improved delivery of molecularly targeted agents upon modulation of multidrug resistance efflux proteins at mouse blood brain barrier en_US
dc.type Thesis en_US
thesis.degree.discipline Pharmaceutical Sciences and Chemistry en
thesis.degree.grantor University of Missouri--Kansas City en
thesis.degree.name Ph.D. en
thesis.degree.level Doctoral en


This item appears in the following Collection(s)

[-] show simple item record